Literature DB >> 2509116

Interleukin-2 can induce suppression of human natural killer cell cytotoxicity.

K Hellstrand1, S Hermodsson.   

Abstract

By interaction with monocytes, interleukin-2 (IL-2) suppressed natural killer (NK) cell cytotoxicity (NKCC) of human, Percoll-fractionated, low-density mononuclear cells. The NK-suppressive effect of IL-2 was independent of de novo formation of prostaglandins or protein since it was unaffected by treatment with indomethacin and cycloheximide, respectively. A monoclonal antibody to the p55 (beta) moiety of the IL-2 receptor (anti-Tac/anti-CD25) blocked IL-2-induced NKCC suppression but did not affect the NK-enhancing effect of the lymphokine. We conclude that IL-2 exerts a monocyte-dependent, IL-2 beta-receptor mediated suppressive influence on human NK cells.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2509116      PMCID： PMC1542047     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


  28 in total

1.  Effects of natural and recombinant IL 2 on regulation of IFN gamma production and natural killer activity: lack of involvement of the Tac antigen for these immunoregulatory effects.

Authors:  J R Ortaldo; A T Mason; J P Gerard; L E Henderson; W Farrar; R F Hopkins; R B Herberman; H Rabin
Journal:  J Immunol       Date:  1984-08       Impact factor: 5.422

Review 2.  Interleukin-2 and the regulation of natural killer activity in cultured cell populations.

Authors:  C G Brooks; C S Henney
Journal:  Contemp Top Mol Immunol       Date:  1985

3.  T cell enrichment and depletion of human peripheral blood mononuclear cell preparations. Unexpected findings in the study of the functional activities of the separated populations.

Authors:  R M Falkoff; M Peters; A S Fauci
Journal:  J Immunol Methods       Date:  1982       Impact factor: 2.303

4.  The differential effects of human leukocyte pyrogen/lymphocyte-activating factor, T cell growth factor, and interferon on human natural killer activity.

Authors:  R A Dempsey; C A Dinarello; J W Mier; L J Rosenwasser; M Allegretta; T E Brown; D R Parkinson
Journal:  J Immunol       Date:  1982-12       Impact factor: 5.422

5.  Isolation of human NK cells by density gradient centrifugation.

Authors:  T Timonen; E Saksela
Journal:  J Immunol Methods       Date:  1980       Impact factor: 2.303

Review 6.  The development of new immunotherapies for the treatment of cancer using interleukin-2. A review.

Authors:  S A Rosenberg
Journal:  Ann Surg       Date:  1988-08       Impact factor: 12.969

7.  Interleukin 2 dependence of human natural killer (NK) cell activity.

Authors:  W Domzig; B M Stadler; R B Herberman
Journal:  J Immunol       Date:  1983-04       Impact factor: 5.422

8.  In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2.

Authors:  M T Lotze; L W Frana; S O Sharrow; R J Robb; S A Rosenberg
Journal:  J Immunol       Date:  1985-01       Impact factor: 5.422

9.  Cyclic AMP as a mediator of prostaglandin E-induced suppression of human natural killer cell activity.

Authors:  T Goto; R B Herberman; A Maluish; D M Strong
Journal:  J Immunol       Date:  1983-03       Impact factor: 5.422

10.  Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.

Authors:  A Mazumder; S A Rosenberg
Journal:  J Exp Med       Date:  1984-02-01       Impact factor: 14.307
View more
  1 in total

1.  Suppression of monocyte and neutrophil function by recombinant IL-2.

Authors:  S E Smith; G D Warren; Y H Thong; J G McCormack
Journal:  Mediators Inflamm       Date:  1993       Impact factor: 4.711
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.